MarginsXMarginsX
Home › Markets › Health Care › PBYI

Puma Biotechnology Inc (PBYI)

PBYI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.34
-5.53% on the day
Market cap
$379.5M
Small cap
Revenue · 2025
$228.4M
-0.9% on 2024
Net income · 2025
$31.1M
13.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1401667/000143774926005891/0001437749-26-005891-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPBYI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001401667
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$228.4M
Net income$31.1M
Operating income$37.3M
Net margin13.6%
Operating margin16.3%
Revenue growth-0.9%
Cash$29.6M
Total assets$216.3M
P/E (computed)12.2×
P/S (computed)1.7×

Warning signs

Cash runway
Cash-flow positive
$41.5M cash at September 30, 2026
Share count, 1 year
+2.6%
2025-11-03 to 2026-11-02 · +8.7% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$2.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$41.5M cash; operating cash flow $11.5M a quarter.Report 2026-09-30
Shares outstanding51,698,356 (2026-11-02); 50,391,107 a year earlier; 47,571,332 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$55.1M$6.0M$14.6M$41.5M$0$231.8M10-Q 2026-11-09
Q2 2026
2026-06-30
$56.5M$8.2M$1.6M$36.5M$0$231.2M10-Q 2026-08-06
Q1 2026
2026-03-31
$44.8M-$3.8M$15.4M$36.2M$11.3M$227.2M10-Q 2026-05-07
Q4 2025
2025-12-31
$75.5M$13.4M$14.4M$29.6M$22.7M$228.4M10-K 2026-02-26
Q3 2025
2025-09-30
$54.5M$8.8M$9.7M$53.5M$34.0M$212.0M10-Q 2026-11-09
Q2 2025
2025-06-30
$52.4M$5.9M$14.1M$54.7M$45.3M$238.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$46.0M$3.0M$3.6M$63.0M$56.7M$232.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$59.1M$19.3M$15.6M$69.2M$68.0M$230.5M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B3
424B32022-08-02
Latest annual report
FORM 10-K
10-K2026-02-26
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-09
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxy
FORM DEFA14A
DEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.8%
1 month-23.2%
3 months-10.8%
Year to date+30.6%
1 year+57.0%
From 52-week high-31.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
PEPGPepGen Inc.$4.19-3.90%$395.0M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M
PRTAProthena Corporation plc$7.97-2.33%$409.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier